Abstracts tagged "Diagnostic Tests"

Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…
Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting
The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Chaim Putterman¹, Michelle Petri², Roberto Caricchio³, Jim C. Oates⁴, Pennina Safer⁵, Keren Jakobi-Brook⁵, Rachel Sorek⁵, Ilana Gluzman⁵, Steve Wallace⁶ and Irun R. Cohen^5,7, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, ⁴Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁶ImmunArray Inc., VA, USA, Richmond, VA, ⁷Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
Abstract Number: 2312 • 2017 ACR/ARHP Annual Meeting
Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Quest Diagnostics Nichols Institute, clemente, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Paul Studenic¹, Farideh Alasti², Daniel Aletaha³, Josef S. Smolen¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
Abstract Number: 2993 • 2017 ACR/ARHP Annual Meeting
Knee Joint Sounds: A Non-Invasive Modality for Classifying Knee Joint Health in Juvenile Idiopathic Arthritis
Daniel Whittingslow¹, Beren Semiz², Lori Ponder³, Patricia Vega-Fernandez⁴, Omer Inan⁵ and Sampath Prahalad⁶, ¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁵Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ⁶Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common, chronic, childhood rheumatic disease and an important cause of disability. It is characterized by persistent inflammation…
Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴quest diagnostics Nichols Institue, clemente, CA, ⁵Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ⁶Childrens Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 71 • 2017 Pediatric Rheumatology Symposium
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Claas Hinze¹, Dirk Holzinger¹, Elke Lainka², Johannes Peter Haas³, Tilmann Kallinich⁴, Ulrich Neudorf², Helmut Wittkowski¹, Gerd Horneff⁵, Dirk Foell⁶ and PRO-KIND study group on SJIA, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Essen, Essen, Germany, ³Center for Pediatric and Adolescent Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁴Charite, University Medicine Berlin, Berlin, Germany, ⁵Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁶Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is currently classified by the International League of Associations for Rheumatology (ILAR) classification criteria. It is characterized by severe…
Abstract Number: 512 • 2016 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons
Yoichiro Haji¹, Ryo Rokutanda², Mitsumasa Kishimoto² and Masato Okada², ¹Rheumatology, Daido Hospital, Nagoya, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: To evaluate anti-cyclic citrullinated protein antibody positivity in the general population and to identify its prognosis. Methods: Anti-cyclic citrullinated protein antibody (ACPA) were measured…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 815 • 2016 ACR/ARHP Annual Meeting
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Petra Budde¹, Hans-Dieter Zucht¹, Peter Schulz-Knappe¹, Prof. Dr. Matthias Schneider², Suzana Jordan³, Oliver Distler³, Britta Maurer³ and Nicolas Hunzelmann⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral…
Abstract Number: 853 • 2016 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis
John Pauling^1,2, Hui Lu¹, Zoe Betteridge^1,2, Gloria Salazar³, Shervin Assassi³, Maureen D Mayes³ and Neil J. McHugh^1,4, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies can be characterized in up to 95% of patients with systemic sclerosis (SSc) and provide enormous diagnostic and prognostic value in the clinical…
Abstract Number: 1334 • 2016 ACR/ARHP Annual Meeting
Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Uveitis represents a diagnostic and therapeutic challenge, as well as an economic one, due to its heterogeneous presentation, multiple underlying causes and lack of…
Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
JoAnn Ball¹, Kelsy Greenwald¹, Atul A. Deodhar² and Kevin L. Winthrop³, ¹Rheumatology, Desert Medical Advances, Palm Desert, CA, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Oregon Health and Sciences University, Portland, OR
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…
Abstract Number: 1892 • 2016 ACR/ARHP Annual Meeting
Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement
Lorinda Chung¹, David Fiorentino², Robert Gerwien³, Kathleen Jia⁴, Joseph Barten Legutki³, Antonio Valenzuela Vergara⁴, Lisa Zhu⁴, Theodore M. Tarasow³ and Kathryn Sykes³, ¹Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ³HealthTell, Inc, san ramon, CA, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease (CTD) characterized by fibrosis, vascular complications, and inflammation affecting both skin and internal organs. Diagnosis of…
Abstract Number: 1902 • 2016 ACR/ARHP Annual Meeting
Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi⁴, ¹Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan, ⁴Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: Raynaud phenomenon (RP) is known to precede other disease manifestations of systemic sclerosis (SSc), and classically viewed as reversible vasospasm due to functional changes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.